Cadila Of India Shows Promising Test Results For “Polypill”
This article was originally published in PharmAsia News
India's Cadila Pharmaceuticals appears to have a five-drug combination capable of reducing heart disease, according to early clinical trial results. Dubbed the "polypill," it combines blood-pressure, cholesterol-lowering and aspirin drugs into a single pill to reduce heart disease. The trial of just over 2,000 patients showed the combination was capable of reducing heart disease by 60 percent and strokes by half. Cadila sponsored the study of the combination pill, to be provided in a capsule it calls Polycap. (Click here for more
You may also be interested in...
FDA warning to "Genesis II Church of Health and Healing " wasn't its first to the organization about promoting a chlorine dioxide formulation, "Miracle Mineral Solution," as an unapproved new drug. 'Infowars' host Alex Jones also was warned about bogus COVID-19 claims.
The first major revision since 2007 notably provides a legal foundation for special approvals under a public health crisis.
Resolution Medical teamed up with Carbon to introduce more than one million 3D-printed nasal swabs a week to address the shortage for COVID-19 testing.